Evidence map›Paper›PMID 38716629›Full record

ArticleeLife2024

Early acquisition of S-specific Tfh clonotypes after SARS-CoV-2 vaccination is associated with the longevity of anti-S antibodies.

Xiuyuan Lu, Hiroki Hayashi, Eri Ishikawa, Yukiko Takeuchi, Julian Vincent Tabora Dychiao, Hironori Nakagami, Sho Yamasaki

Abstract read
In one paragraph

Article in eLife, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiuyuan Lu *Laboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University, Suita, Japan.ORCID https://orcid.org/0000-0002-0784-2871
Hiroki Hayashi *Department of Health Development and Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
Eri Ishikawa *Laboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University, Suita, Japan.
Yukiko TakeuchiLaboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University, Suita, Japan.
Julian Vincent Tabora DychiaoLaboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University, Suita, Japan.
Hironori NakagamiDepartment of Health Development and Medicine, Osaka University Graduate School of Medicine, Suita, Japan.ORCID https://orcid.org/0000-0003-4494-3601
Sho YamasakiLaboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University, Suita, Japan.ORCID https://orcid.org/0000-0002-5184-6917

Funding

Japan Agency for Medical Research and Development JP21ym0126049Japan Agency for Medical Research and Development JP223fa627002Japan Agency for Medical Research and Development JP223fa727001Japan Agency for Medical Research and Development JP23ym0126049Japan Society for the Promotion of Science JP20H00505Japan Society for the Promotion of Science JP22H05182Japan Society for the Promotion of Science JP22H05183
6 · The paper itself

Abstract

SARS-CoV-2 vaccines have been used worldwide to combat COVID-19 pandemic. To elucidate the factors that determine the longevity of spike (S)-specific antibodies, we traced the characteristics of S-specific T cell clonotypes together with their epitopes and anti-S antibody titers before and after BNT162b2 vaccination over time. T cell receptor (TCR) αβ sequences and mRNA expression of the S-responded T cells were investigated using single-cell TCR- and RNA-sequencing. Highly expanded 199 TCR clonotypes upon stimulation with S peptide pools were reconstituted into a reporter T cell line for the determination of epitopes and restricting HLAs. Among them, we could determine 78 S epitopes, most of which were conserved in variants of concern (VOCs). After the 2nd vaccination, T cell clonotypes highly responsive to recall S stimulation were polarized to follicular helper T (Tfh)-like cells in donors exhibiting sustained anti-S antibody titers (designated as 'sustainers'), but not in 'decliners'. Even before vaccination, S-reactive CD4

Indexed as

Antibodies, ViralBNT162 VaccineCOVID-19COVID-19 VaccinesSARS-CoV-2Spike Glycoprotein, CoronavirusVaccinationAdultEpitopes, T-LymphocyteFemaleHumansMaleMiddle AgedT-Lymphocytes, Helper-InducerAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesEpitopes, T-LymphocyteSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2antibody longevityclonotypic tracinghumanimmunologyinflammationSARS-CoV-2T cell responseTfh cellsvaccine

Identifiers

PMID38716629
PMCPMC11078543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.